Mechanism of action
BRAFTOVI + cetuximab target the aggressive biology of BRAF V600E-mutant mCRC
Dual inhibition of the MAPK pathway with BRAFTOVI in combination with cetuximab increases anti-tumour activity and reduces mechanisms of resistance1,8
Mechanism of Disease
BRAF mutations persistently activate the MAPK pathway,
which can stimulate tumor cell growth and proliferation.
BRAFTOVI targets BRAF V600E, which drives persistent MAPK signaling.
BRAFTOVI is a BRAF kinase inhibitor that binds to BRAF V600E.
Reactivation through EGFR
BRAF inhibition alone leads to reactivation
of the MAPK pathway through EGFR.
Dual inhibition of EGFR and BRAF
BRAFTOVI in combination with cetuximab reduces MAPK reactivation
through EGFR-adaptive feedback.
Cetuximab is an antagonistic, monoclonal antibody that binds to EGFR.
Combined EGFR and BRAF inhibition reduces reactivation
of MAPK signaling.